Flow cytometric analysis of myelodysplasia: Pre-analytical and technical issues-Recommendations from the European LeukemiaNet

V.H.J. van der Velden; F. Preijers; U. Johansson; T.M. Westers; A. Dunlop; A. Porwit; M.C. Bene; P. Valent; J. te Marvelde; O. Wagner-Ballon; U. Oelschlaegel; L. Saft; S. Kordasti; R. Ireland; E. Cremers; C. Alhan; C. Duetz; W. Hobo; N. Chapuis; M. Fontenay; P. Bettelheim; L. Eidenshink-Brodersen; P. Font; M.R. Loken; S. Matarraz; K. Ogata; A. Orfao; K. Psarra; D. Subira; D.A. Wells; M.G. Della Porta; K. Burbury; F. Bellos; E. Weiss; W. Kern; A. van de Loosdrecht

doi:10.1002/cyto.b.22046

Flow cytometric analysis of myelodysplasia: Pre-analytical and technical issues-Recommendations from the European LeukemiaNet

V.H.J. van der Velden^*, F. Preijers, U. Johansson, T.M. Westers, A. Dunlop, A. Porwit, M.C. Bene, P. Valent, J. te Marvelde, O. Wagner-Ballon, U. Oelschlaegel, L. Saft, S. Kordasti, R. Ireland, E. Cremers, C. Alhan, C. Duetz, W. Hobo, N. Chapuis, M. FontenayP. Bettelheim, L. Eidenshink-Brodersen, P. Font, M.R. Loken, S. Matarraz, K. Ogata, A. Orfao, K. Psarra, D. Subira, D.A. Wells, M.G. Della Porta, K. Burbury, F. Bellos, E. Weiss, W. Kern, A. van de Loosdrecht

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Background Flow cytometry (FCM) aids the diagnosis and prognostic stratification of patients with suspected or confirmed myelodysplastic syndrome (MDS). Over the past few years, significant progress has been made in the FCM field concerning technical issues (including software and hardware) and pre-analytical procedures. Methods Recommendations are made based on the data and expert discussions generated from 13 yearly meetings of the European LeukemiaNet international MDS Flow working group. Results We report here on the experiences and recommendations concerning (1) the optimal methods of sample processing and handling, (2) antibody panels and fluorochromes, and (3) current hardware technologies. Conclusions These recommendations will support and facilitate the appropriate application of FCM assays in the diagnostic workup of MDS patients. Further standardization and harmonization will be required to integrate FCM in MDS diagnostic evaluations in daily practice.

Original language	English
Pages (from-to)	15-26
Number of pages	12
Journal	Cytometry Part B-clinical Cytometry
Volume	104
Issue number	1
Early online date	11 Dec 2021
DOIs	https://doi.org/10.1002/cyto.b.22046
Publication status	Published - Jan 2023

Keywords

ELN
flow cytometry
MDS
pre-analytic issues
BONE-MARROW
REFRACTORY CYTOPENIA
CONSENSUS STATEMENTS
DIAGNOSTIC-CRITERIA
LOW-GRADE
CLASSIFICATION
MASTOCYTOSIS
STANDARDS
QUANTIFICATION

Access to Document

10.1002/cyto.b.22046Licence: CC BY

Cite this

van der Velden, V. H. J., Preijers, F., Johansson, U., Westers, T. M., Dunlop, A., Porwit, A., Bene, M. C., Valent, P., te Marvelde, J., Wagner-Ballon, O., Oelschlaegel, U., Saft, L., Kordasti, S., Ireland, R., Cremers, E., Alhan, C., Duetz, C., Hobo, W., Chapuis, N., ... van de Loosdrecht, A. (2023). Flow cytometric analysis of myelodysplasia: Pre-analytical and technical issues-Recommendations from the European LeukemiaNet. Cytometry Part B-clinical Cytometry, 104(1), 15-26. https://doi.org/10.1002/cyto.b.22046

@article{e0a3d00f383e4e4aaceb38130c6cc79d,

title = "Flow cytometric analysis of myelodysplasia: Pre-analytical and technical issues-Recommendations from the European LeukemiaNet",

abstract = "Background Flow cytometry (FCM) aids the diagnosis and prognostic stratification of patients with suspected or confirmed myelodysplastic syndrome (MDS). Over the past few years, significant progress has been made in the FCM field concerning technical issues (including software and hardware) and pre-analytical procedures. Methods Recommendations are made based on the data and expert discussions generated from 13 yearly meetings of the European LeukemiaNet international MDS Flow working group. Results We report here on the experiences and recommendations concerning (1) the optimal methods of sample processing and handling, (2) antibody panels and fluorochromes, and (3) current hardware technologies. Conclusions These recommendations will support and facilitate the appropriate application of FCM assays in the diagnostic workup of MDS patients. Further standardization and harmonization will be required to integrate FCM in MDS diagnostic evaluations in daily practice.",

keywords = "ELN, flow cytometry, MDS, pre-analytic issues, BONE-MARROW, REFRACTORY CYTOPENIA, CONSENSUS STATEMENTS, DIAGNOSTIC-CRITERIA, LOW-GRADE, CLASSIFICATION, MASTOCYTOSIS, STANDARDS, QUANTIFICATION",

author = "{van der Velden}, V.H.J. and F. Preijers and U. Johansson and T.M. Westers and A. Dunlop and A. Porwit and M.C. Bene and P. Valent and {te Marvelde}, J. and O. Wagner-Ballon and U. Oelschlaegel and L. Saft and S. Kordasti and R. Ireland and E. Cremers and C. Alhan and C. Duetz and W. Hobo and N. Chapuis and M. Fontenay and P. Bettelheim and L. Eidenshink-Brodersen and P. Font and M.R. Loken and S. Matarraz and K. Ogata and A. Orfao and K. Psarra and D. Subira and D.A. Wells and {Della Porta}, M.G. and K. Burbury and F. Bellos and E. Weiss and W. Kern and {van de Loosdrecht}, A.",

year = "2023",

month = jan,

doi = "10.1002/cyto.b.22046",

language = "English",

volume = "104",

pages = "15--26",

journal = "Cytometry Part B-clinical Cytometry",

issn = "1552-4949",

publisher = "Wiley-Liss Inc.",

number = "1",

}

van der Velden, VHJ, Preijers, F, Johansson, U, Westers, TM, Dunlop, A, Porwit, A, Bene, MC, Valent, P, te Marvelde, J, Wagner-Ballon, O, Oelschlaegel, U, Saft, L, Kordasti, S, Ireland, R, Cremers, E, Alhan, C, Duetz, C, Hobo, W, Chapuis, N, Fontenay, M, Bettelheim, P, Eidenshink-Brodersen, L, Font, P, Loken, MR, Matarraz, S, Ogata, K, Orfao, A, Psarra, K, Subira, D, Wells, DA, Della Porta, MG, Burbury, K, Bellos, F, Weiss, E, Kern, W & van de Loosdrecht, A 2023, 'Flow cytometric analysis of myelodysplasia: Pre-analytical and technical issues-Recommendations from the European LeukemiaNet', Cytometry Part B-clinical Cytometry, vol. 104, no. 1, pp. 15-26. https://doi.org/10.1002/cyto.b.22046

TY - JOUR

T1 - Flow cytometric analysis of myelodysplasia: Pre-analytical and technical issues-Recommendations from the European LeukemiaNet

AU - van der Velden, V.H.J.

AU - Preijers, F.

AU - Johansson, U.

AU - Westers, T.M.

AU - Dunlop, A.

AU - Porwit, A.

AU - Bene, M.C.

AU - Valent, P.

AU - te Marvelde, J.

AU - Wagner-Ballon, O.

AU - Oelschlaegel, U.

AU - Saft, L.

AU - Kordasti, S.

AU - Ireland, R.

AU - Cremers, E.

AU - Alhan, C.

AU - Duetz, C.

AU - Hobo, W.

AU - Chapuis, N.

AU - Fontenay, M.

AU - Bettelheim, P.

AU - Eidenshink-Brodersen, L.

AU - Font, P.

AU - Loken, M.R.

AU - Matarraz, S.

AU - Ogata, K.

AU - Orfao, A.

AU - Psarra, K.

AU - Subira, D.

AU - Wells, D.A.

AU - Della Porta, M.G.

AU - Burbury, K.

AU - Bellos, F.

AU - Weiss, E.

AU - Kern, W.

AU - van de Loosdrecht, A.

PY - 2023/1

Y1 - 2023/1

N2 - Background Flow cytometry (FCM) aids the diagnosis and prognostic stratification of patients with suspected or confirmed myelodysplastic syndrome (MDS). Over the past few years, significant progress has been made in the FCM field concerning technical issues (including software and hardware) and pre-analytical procedures. Methods Recommendations are made based on the data and expert discussions generated from 13 yearly meetings of the European LeukemiaNet international MDS Flow working group. Results We report here on the experiences and recommendations concerning (1) the optimal methods of sample processing and handling, (2) antibody panels and fluorochromes, and (3) current hardware technologies. Conclusions These recommendations will support and facilitate the appropriate application of FCM assays in the diagnostic workup of MDS patients. Further standardization and harmonization will be required to integrate FCM in MDS diagnostic evaluations in daily practice.

AB - Background Flow cytometry (FCM) aids the diagnosis and prognostic stratification of patients with suspected or confirmed myelodysplastic syndrome (MDS). Over the past few years, significant progress has been made in the FCM field concerning technical issues (including software and hardware) and pre-analytical procedures. Methods Recommendations are made based on the data and expert discussions generated from 13 yearly meetings of the European LeukemiaNet international MDS Flow working group. Results We report here on the experiences and recommendations concerning (1) the optimal methods of sample processing and handling, (2) antibody panels and fluorochromes, and (3) current hardware technologies. Conclusions These recommendations will support and facilitate the appropriate application of FCM assays in the diagnostic workup of MDS patients. Further standardization and harmonization will be required to integrate FCM in MDS diagnostic evaluations in daily practice.

KW - ELN

KW - flow cytometry

KW - MDS

KW - pre-analytic issues

KW - BONE-MARROW

KW - REFRACTORY CYTOPENIA

KW - CONSENSUS STATEMENTS

KW - DIAGNOSTIC-CRITERIA

KW - LOW-GRADE

KW - CLASSIFICATION

KW - MASTOCYTOSIS

KW - STANDARDS

KW - QUANTIFICATION

U2 - 10.1002/cyto.b.22046

DO - 10.1002/cyto.b.22046

M3 - Article

C2 - 34894176

SN - 1552-4949

VL - 104

SP - 15

EP - 26

JO - Cytometry Part B-clinical Cytometry

JF - Cytometry Part B-clinical Cytometry

IS - 1

ER -